Bifidobacterium longum: strains and forms

How to distinguish B. longum strains, live cultures and inactivated cells.

Key points

  • BB536, NCC3001, 1714, 35624, ES1, BL21 and APC1472 are different strains with separate studies. Check the full code and composition: a result for BB536 does not automatically describe a blend with another strain. [1] [2] [3] [4] See the evidence 1
  • For a live product, check the CFU count through the end of shelf life and storage conditions; a higher number does not necessarily mean greater benefit. Heated CLA8013 and HT-ES1 were studied as inactivated cells, not as a dose of live bacteria. [1] [2] [3] [4] See the evidence 1
  • Ordinary yogurt does not necessarily contain BB536. Look for the specific strain and its amount on the package. [5] [1] See the evidence 1

Practical guide

Check the findings and their applicability to your situation.

Check the exact strain and product form: studies concern specific cultures.

Key points

Why these conclusions

Strains, cells and products

Live strains have separate studies. In an early publication, 35624 was called B. infantis 35624; in the trial of pain in IBS, the specific dose of 100 million CFU daily showed an advantage. [1] [2] [3] [4]

CLA8013 and HT-ES1 were inactivated by heating in the studies described. For HT-ES1, 2.5 billion cells were used in digestive studies and 2 billion for allergic rhinitis. [1] [2] [3] [4]

In the yogurt studied, a daily serving contained about 2 billion CFU of BB536; the study examined bacterial survival, not symptoms. An ordinary starter culture does not establish the presence of this strain. [5] [1]

Information from the source

Live bacteria. BB536, NCC3001, 1714, 35624, ES1, BL21 and APC1472 are different strains. Look on the package for the full code, CFU count through the end of shelf life and storage conditions. More CFU alone does not mean more benefit. Inactivated cells. CLA8013 and HT-ES1 were heat-treated in these trials. Their doses are expressed as numbers of cells or cell equivalents, not numbers of live bacteria. Even for HT-ES1, doses differed: 2.5 billion cells in digestive studies and 2 billion for allergic rhinitis. Strain 35624. In an early publication it was called B. infantis 35624. In the trial of pain in IBS, capsules containing 100 million CFU daily showed an advantage; this is not a general result for all doses or all B. longum products. [1] [2] [3] [4]

Information from the source

B. longum is found in foods with a specifically added culture, such as yogurt with BB536. In the yogurt studied, a daily serving contained about 2 billion CFU of BB536; the study examined bacterial survival, not symptom reduction. Look on the package for the specific strain, amount per serving, expiration date and storage conditions. Ordinary starter cultures in yogurt, kefir or fermented vegetables do not establish the presence of the desired B. longum strain. [5] [1]

Information from the source

In healthy people, live probiotics can cause gas and other intestinal complaints. Inactivated cells also do not rule out adverse reactions: the HT-ES1 trial described stomach pain, gas and a possible association with nausea, bloating and reflux. In severe illness or markedly weakened immunity, live probiotics may increase the risk of infection. In these situations, discuss product choice and monitoring with a doctor. The risk is particularly important for preterm infants: the FDA described a case of B. longum sepsis and the death of an infant after a hospital product containing live bacteria. This case does not establish the frequency of complications in healthy adults. Check not only the bacteria but also the other ingredients. For example, the CLA8013 capsule shell in the trial described contained porcine gelatin and soy lecithin; another product may have a different composition. [3] [2] [6] [7] [1]

More details

Safety

In cases of severe illness or markedly weakened immunity, discuss the choice of a live probiotic with a doctor because of the risk of infection. [3] [2] [6] [7] [1]

Sources

  1. Probiotics — Fact Sheet for Consumers (NIH ODS). https://ods.od.nih.gov/factsheets/Probiotics-Consumer/
  2. Effects of Bifidobacterium longum CLA8013 on bowel movement improvement: a placebo-controlled, randomized, double-blind study. https://pubmed.ncbi.nlm.nih.gov/37404567/
  3. Effect of Postbiotic Bifidobacterium longum CECT 7347 on Gastrointestinal Symptoms, Serum Biochemistry, and Intestinal Microbiota in Healthy Adults: A Randomised, Parallel, Double-Blind, Placebo-Controlled Pilot Study. https://pubmed.ncbi.nlm.nih.gov/39599737/
  4. Efficacy of an encapsulated probiotic Bifidobacterium infantis 35624 in women with irritable bowel syndrome. https://pubmed.ncbi.nlm.nih.gov/16863564/
  5. Probiotic viability in the gastrointestinal tract in a randomised placebo controlled trial: combining molecular biology and novel cultivation techniques. https://pubmed.ncbi.nlm.nih.gov/39814039/
  6. Risk of Invasive Disease in Preterm Infants Given Probiotics Formulated to Contain Live Bacteria or Yeast (FDA). https://www.fda.gov/safety/medical-product-safety-information/risk-invasive-disease-preterm-infants-given-probiotics-formulated-contain-live-bacteria-or-yeast
  7. Probiotics: Usefulness and Safety (NCCIH). https://www.nccih.nih.gov/health/probiotics-usefulness-and-safety

Methodology: Subpages evidence-led supplement pipeline v1

Ingredient overview: Bifidobacterium longum